Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 657 of 5804
-
New drug cocktail aims to tackle lymphoma without chemo
Disease control Recruiting nowBrUOG-401 is a prospective, single-arm, phase 2 trial of first-line therapy in adult patients with previously untreated FL or MZL. All patients will be assigned the same initial treatment plan, modified by interim response assessment (IRA) after Cycle 4. All patients will start t…
Phase: PHASE2 • Sponsor: Brown University • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New drug aims to tame rare inflammatory disease
Disease control OngoingThis study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New cream could soothe stubborn hand eczema in teens
Disease control CompletedThe purpose of this trial is to test if delgocitinib cream is effective in treating chronic hand eczema (CHE) and to find out what side effects it may have compared with a cream vehicle with no active medical ingredient in adolescents aged 12-17 years. At each visit to the clinic…
Phase: PHASE3 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New pill shows promise for severe eczema in major trial
Disease control OngoingA multicenter, randomized, double-blind, placebo-controlled phase III clinical study of jaktinib hydrochloride tablets in the treatment of adult patients with moderate and severe atopic dermatitis
Phase: PHASE3 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Phage therapy takes on superbug UTIs in new trial
Disease control Recruiting nowThis is a Phase 2 superiority study of LBP-EC01, a recombinant bacteriophage cocktail, with an initial open-label 3-arm pharmacokinetic (PK) lead-in portion of 30 patients to evaluate the optimal dosing regimen to be used in the subsequent 288 patient blinded portion of the study…
Phase: PHASE2 • Sponsor: Locus Biosciences • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug shows promise in preventing hereditary swelling attacks
Disease control OngoingThe purpose of this study is to evaluate the long-term safety and efficacy of donidalorsen in people with HAE and the effects of donidalorsen on the number of HAE attacks and their impact on quality of life (QoL).
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Targeted drug aims to stop blood cancer return after transplant
Disease control OngoingIn this study, tagraxofusp (Tag) is given to patients with CD 123+ myelofibrosis (MF), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) after allogeneic stem cell transplant (HCT) to help prevent relapse. Patients will receive up to about 9 cycles of treat…
Phase: PHASE1 • Sponsor: Karen Ballen, MD • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Promising new combo tackles rare, aggressive cancer
Disease control Recruiting nowThis phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with cisplatin and etoposide or carboplatin and paclitaxel in treating patients with NUT carcinoma. Another purpose of this study is to see whether there are any changes in patient's tumo…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Promising cocktail targets tough lung cancer
Disease control OngoingThis study aims to establish a safe and well tolerated dose of \[177Lu\]Lu-DOTA-TATE in combination with carboplatin, etoposide and atezolizumab in this setting and to assess preliminary efficacy of this combination treatment versus the combination of carboplatin, etoposide, and …
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New study targets psoriasis treatment gap in skin of color patients
Disease control CompletedThe purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-to-severe body psoriasis or predominant moderate-to-severe scalp psoriasis by assessing improvements in the signs and symptoms of p…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can newer blood thinners beat aspirin for clot prevention in blood cancer patients?
Disease control Recruiting nowPhiladelphia-negative myeloproliferative neoplasms (MPN) are frequent and chronic myeloid malignancies including Polycythemia Vera (PV), essential thrombocythemia (ET), Primary Myelofibrosis (PMF) and Prefibrotic myelofibrosis (PreMF). These MPNs are caused by the acquisition of …
Phase: PHASE3 • Sponsor: University Hospital, Brest • Aim: Disease control
Last updated Jun 27, 2026 11:04 UTC
-
Keytruda may let some bladder cancer patients avoid bladder removal
Disease control OngoingSubjects with cT2-T3N0M0 urothelial cancer of the bladder will be enrolled. After completing two cycles of pembrolizumab, subjects will undergo a restaging MRI of the abdomen and pelvis with a standard acquisition protocol (as outlined in the protocol) as well as CT chest. A CT o…
Phase: PHASE2 • Sponsor: Matthew Galsky • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New hope for hard-to-treat lung cancer: targeted drug shows promise
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of T-DXd in participants with HER2 mutant metastatic non-squamous NSCLC.
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for rare blood cancers: first human trial launches
Disease control Recruiting nowThis is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas
Phase: PHASE1, PHASE2 • Sponsor: Dren Bio • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New chemo combo shows promise for Hard-to-Treat stomach and esophageal cancers
Disease control Recruiting nowThe primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of progression free survival (PFS) and overall survival (OS).…
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New 21-Valent vaccine aims to shield HIV patients from pneumococcal disease
Prevention CompletedThis study will evaluate the safety, tolerability, and immunogenicity of a pneumococcal 21-valent conjugate vaccine (V116) in persons living with human immunodeficiency virus (HIV), for the prevention of pneumococcal disease caused by the serotypes in the vaccine.
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated Jun 27, 2026 09:02 UTC
-
AI blood test could spot endometriosis without surgery
Diagnosis Recruiting nowThe goal of this observational study is to determine the clinical validity of a deep neural network algorithm that utilizes protein biomarker detection of Endometriosis - "EndoCheck" - as an "aid in diagnosis" for endometriosis and to show validity as a diagnostic test
Sponsor: Aspira Women's Health • Aim: Diagnosis
Last updated Jun 27, 2026 13:02 UTC
-
Immune cells engineered to attack brain tumors enter human testing
Disease control Recruiting nowThis is an open label, non-randomized, single site Phase I study to test the manufacturing feasibility and safety of locoregional (LR) administration of B7-H3CART into the central nervous system of adult subjects with recurrent IDH wild-type GBM using a standard 3+3 dose escalati…
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
First mRNA vaccine against deadly nipah virus shows promise in early trial
⭐️ VACCINE ⭐️ CompletedBackground: Nipah virus (NiV) is transmitted from animals to humans, from humans to humans, and through contaminated food. Infected people may have a cough and trouble breathing. Some people may develop serious symptoms, such as brain infection and inflammation, that can lead to…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:55 UTC
-
Can cash incentives and a quit-smoking pill curb both drinking and smoking?
Disease control Recruiting nowUsing a randomized controlled trial (RCT), the goal of this study is to evaluate the ability of evidence based behavioral treatment (contingency management: CM) to significantly decrease alcohol use and cigarette smoking among treatment-seeking smokers with an alcohol use disorde…
Phase: PHASE2 • Sponsor: Washington State University • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC